Celldex: Fourth Quarter Financial Overview

Celldex Therapeutics Reports Fourth Quarter Financial Results

Celldex Therapeutics Inc., based in Hampton, New Jersey, announced on Wednesday that it recorded a net loss of $81.3 million for the fourth quarter.

This translates to a quarterly loss of $1.22 per share, which was greater than what analysts had anticipated. According to Zacks Investment Research, six analysts had projected a loss of $1 per share.

The company, which specializes in biopharmaceuticals, generated $121,000 in revenue during the quarter, falling short of the $1.4 million expected by three analysts surveyed by Zacks.

For the entire year, Celldex reported a total loss of $258.8 million, or $3.90 per share, with annual revenue reaching $1.5 million.

Financial data for this article was provided by Zacks Investment Research and the story was produced by Automated Insights.